Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Challenges and Advances in Ocular Mucous Membrane Pemphigoid (Ommp); From Pathogenesis to Treatment Strategies Publisher



Ghanbari H1 ; Rahimi M1 ; Momeni A1 ; Aminizade M1 ; Nozarian Z1 ; Moghtader A2 ; Rubinstein DE3 ; Basu S2 ; Sangwan VS4 ; Djalilian AR2 ; Soleimani M3, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Eye Research Center, Farabi Eye Hospital, Qazvin Sq, Tehran, Iran
  2. 2. Department of Ophthalmology and Visual Science, Cornea Service, Eye and Ear Infirmary, University of IL, University of Illinois at Chicago, Chicago, IL, United States
  3. 3. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
  4. 4. Stem Cell, Dr. Shroff’s Charity Eye Hospital, Delhi, Delhi, India
  5. 5. Faculty Member of the AI.Health4All Center for Health Equity Using Machine Learning and Artificial Intelligence, University of Illinois at Chicago, Chicago, IL, United States

Source: Graefe's Archive for Clinical and Experimental Ophthalmology Published:2025


Abstract

Purpose: Mucous membrane pemphigoid (MMP) is a systemic autoimmune condition characterized by blistering and cicatrization, predominantly affecting mucous membranes, including those lining the esophagus, oropharynx, nasal cavity, trachea, conjunctiva, and genitalia. Ocular mucous membrane pemphigoid (OMMP) is observed in approximately 70% of MMP cases. This study aims to review the pathophysiology, clinical manifestations, diagnosis, treatment, and complications of OMMP. Methods: A literature search was conducted using MEDLINE and EMBASE databases. Results: OMMP is characterized by the deposition of autoantibodies along the basement membrane zone of mucous membranes, particularly affecting the conjunctival epithelium. OMMP manifests as chronic ocular discomfort, inflammation, conjunctival scarring, eyelid abnormalities, and visual impairment. Given the extensive range of similar conditions, including drug-induced pseudo-pemphigoid and paraneoplastic conjunctival cicatrization, challenges in differential diagnosis may arise. The clinical diagnosis of OMMP is supported by confirmatory biopsy with histopathology and immunofluorescence studies. The mainstay of management includes systemic immunomodulatory medications and anti-inflammatory agents, tailored to disease severity. Surgical interventions may be necessary, although caution is warranted due to the risk of exacerbating OMMP. Prompt diagnosis and treatment are essential to halt disease progression and prevent vision loss. Complications of OMMP include corneal disorders, lid disorders, and vision disturbances. A comprehensive understanding of OMMP aids in timely intervention and improved patient outcomes. Conclusion: OMMP is a bilateral, chronic, progressive, relapsing–remitting condition. Early diagnosis and treatment of OMMP are necessary to prevent disease progression. The management of OMMP varies according to the severity of the disease, but often involves both medical control of the underlying inflammatory process and subsequent surgical correction of residual anatomical changes. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.